Global PCOS Treatment Market By Surgery (Ovarian Wedge Resection, Cyst Aspiration, Laparoscopic Ovarian Drilling), By Drug (Ovulation Inducing Agents, Insulin-Sensitizing Agents, Oral Contraceptives, Antiandrogens, Anti-Depressants, Insulin-Sensitizing Agents, Anti-Obesity Drugs, Others), By Diagnosis (Pelvic Examination, Ultrasound, Blood Tests), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Fertility Clinics), By Region, Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.81 Billion
CAGR (2026-2031)	6.53%
Fastest Growing Segment	Insulin-sensitizing agents
Largest Market	North America
Market Size (2031)	USD 7.03 Billion

Market Overview

The Global PCOS Treatment Market will grow from USD 4.81 Billion in 2025 to USD 7.03 Billion by 2031 at a 6.53% CAGR. The Global PCOS Treatment Market is defined by the pharmacological management of polycystic ovary syndrome through therapeutic classes such as insulin-sensitizing agents, oral contraceptives, anti-androgens, and ovulation stimulators. The primary driver fueling market expansion is the rising global incidence of hormonal and metabolic disorders among women of reproductive age, coupled with improved diagnostic infrastructure that facilitates earlier disease detection. According to the World Health Organization, in 2025, polycystic ovary syndrome affects an estimated 6% to 13% of women of reproductive age globally. This substantial prevalence creates a sustained demand for long-term therapeutic regimens to manage symptoms ranging from infertility to metabolic syndrome.

Despite these growth factors, the market faces a significant challenge regarding the high rate of undiagnosed cases which restricts the addressable patient population. The heterogeneous nature of the disorder often leads to clinical oversight or misdiagnosis, preventing a large segment of potential patients from accessing appropriate medical interventions. This diagnostic gap acts as a major restraint on market revenues, as effective treatment penetration relies heavily on accurate and timely identification of the condition in primary care settings.

Key Market Drivers

The rising demand for fertility management and infertility treatments serves as a primary engine for market growth, necessitating the development of advanced therapeutic interventions. As PCOS remains a leading cause of anovulatory infertility, pharmaceutical and biotechnology companies are heavily investing in novel reproductive solutions to address this critical patient need. This surge in commercial focus is evident in the financial activities of emerging biotech firms dedicated to reproductive health. According to Cell & Gene Therapy Review, August 2025, women’s health biotech Gameto closed a $44 million Series C funding round to advance its stem cell-derived fertility therapy, highlighting the robust capital inflow aimed at improving conception outcomes for patients with reproductive disorders. Such investments underscore the industry's pivot toward more sophisticated, targeted fertility treatments that go beyond traditional hormonal management.

Simultaneously, the proliferation of digital health tools and telemedicine is reshaping patient access and chronic care management for the condition. Digital platforms are increasingly bridging the diagnostic gap by offering virtual access to specialized endocrinologists and multidisciplinary care teams, which is essential for a syndrome requiring long-term metabolic monitoring. According to HLTH, January 2025, virtual care platform Allara Health secured $26 million in Series B funding to expand its telehealth services for women with complex hormonal conditions, demonstrating the market's shift toward accessible, technology-driven care models. This expanded access is critical given the massive financial impact of the disorder on healthcare systems. According to Ovia Health, in 2025, PCOS contributes to an annual economic burden exceeding $15 billion in the United States alone, driven largely by unmanaged symptoms and long-term complications.

Download Free Sample Report

Key Market Challenges

The high rate of undiagnosed cases constitutes a critical barrier that directly restricts the revenue potential of the Global PCOS Treatment Market. Because the syndrome manifests through varied symptoms such as metabolic variance and dermatological issues, primary care providers frequently treat these signs in isolation rather than identifying the root hormonal disorder. This clinical oversight prevents a large segment of the affected population from accessing specific therapeutic regimens, thereby significantly shrinking the volume of addressable patients. Consequently, despite the rising incidence of the condition, the market struggles to convert the total disease burden into actionable prescription demand.

According to 'PCOS Challenge, The National Polycystic Ovary Syndrome Association', in 2024, approximately 50% to 70% of individuals with polycystic ovary syndrome went undiagnosed or misdiagnosed. This substantial statistical gap underscores that the majority of potential consumers are invisible to the healthcare system. The inability to capture this patient pool depresses drug sales and limits the return on investment for companies developing specialized treatments, as actual market penetration remains artificially low compared to the true prevalence of the disorder.

Key Market Trends

The market is rapidly pivoting toward metabolic-centric care strategies, specifically through the surging off-label adoption of GLP-1 receptor agonists like semaglutide and tirzepatide. Physicians are increasingly prescribing these advanced pharmacological agents to address the insulin resistance and weight management challenges that are central to the syndrome's pathology, moving beyond traditional oral contraceptives and metformin. This fundamental change in clinical practice is substantiated by real-world evidence showing an explosive uptake of these therapies among the affected patient population. According to ConscienHealth, December 2025, in the article 'Striking Growth of GLP-1s in Women with PCOS', an analysis of electronic health records revealed that prescriptions for semaglutide or tirzepatide rose by more than 700% in women with polycystic ovary syndrome. This dramatic increase highlights a new therapeutic standard where metabolic regulation is becoming a primary treatment objective alongside reproductive health.

Simultaneously, the integration of artificial intelligence in diagnostic and management tools is creating new avenues for personalized, non-pharmacological interventions. Startups are leveraging machine learning algorithms to analyze patient data and tailor lifestyle therapeutics, effectively addressing the heterogeneity of the disorder that often leads to failure in "one-size-fits-all" treatment protocols. This technological evolution is attracting significant venture capital interest as companies seek to digitize and optimize long-term care pathways through precision medicine. According to Women's Tabloid, July 2025, in the article 'Solence secures €1.6 million to transform PCOS care through AI-powered digital therapeutics', the startup raised €1.6 million to enhance its AI-driven program that targets symptoms through tailored lifestyle interventions. Such investments underscore the industry's commitment to developing scalable, data-driven management solutions that offer personalized support outside traditional clinical settings.

Segmental Insights

The Insulin-sensitizing agents segment is currently positioning itself as the fastest-growing category within the Global PCOS Treatment Market. This rapid expansion is primarily driven by the strong clinical correlation between Polycystic Ovary Syndrome and metabolic comorbidities, specifically insulin resistance and type 2 diabetes. Healthcare providers increasingly prescribe these therapeutics to address underlying metabolic dysfunction, which assists in regulating menstrual cycles and improving ovulation. Furthermore, clinical recommendations from established groups such as the Androgen Excess and PCOS Society advocate for managing metabolic risks, thereby reinforcing the adoption of these agents in standard therapeutic protocols.

Regional Insights

North America holds the leading position in the global PCOS treatment market due to widespread patient awareness and a high rate of clinical diagnosis. The region benefits from a developed healthcare sector that ensures accessibility to various therapeutic options. Additionally, the strong presence of key pharmaceutical manufacturers facilitates the continuous availability of treatments. Favorable reimbursement coverage further encourages patient adoption of prescribed therapies. This leadership is reinforced by the proactive role of agencies such as the U.S. Food and Drug Administration in approving medications that manage associated symptoms effectively.

Recent Developments

• In February 2025, Cosette Pharmaceuticals announced an agreement to acquire Mayne Pharma Group in a transaction valued at approximately $430 million to strengthen its portfolio in women's health. This strategic acquisition was designed to combine commercial capabilities and expand the availability of patent-protected products, including a novel oral contraceptive utilized by patients for managing symptoms of polycystic ovary syndrome (PCOS). The consolidation aimed to solidify the company's leadership in the United States and broaden its reach in international markets, ensuring continued access to essential therapies for reproductive health and dermatology.
• In January 2025, Celmatix Inc. launched a new therapeutic drug program focused on developing a novel Jun-N-terminal kinase (JNK) inhibitor to address critical unmet needs in women's health. The company utilized its proprietary multi-omics platform to identify the candidate, which was designed to target inflammation and pain pathways associated with complex conditions, including polycystic ovary syndrome (PCOS) and endometriosis. This development marked a significant step in the company's efforts to create first-line disease-modifying treatments for ovarian health disorders that currently lack effective pharmaceutical options.
• In December 2024, clinical researchers at the University of Oklahoma Health Sciences began leading a pivotal national trial to evaluate a novel medical device for treating infertility related to polycystic ovary syndrome (PCOS). The study, titled REBALANCE, was designed to assess the safety and efficacy of a minimally invasive system that uses ultrasound-guided ablation to restore ovulation in women who had not responded to standard oral medications. This breakthrough research aimed to provide a hormone-free therapeutic alternative for patients, addressing a significant gap in the current standard of care for PCOS-related infertility.
• In October 2024, Wisp launched a comprehensive weight care vertical specifically tailored to support women managing hormonal imbalances, including those diagnosed with polycystic ovary syndrome (PCOS). The new service offered personalized online medical consultations and access to GLP-1 medications and over-the-counter supplements to address metabolic health challenges often associated with the condition. By integrating weight management with reproductive health services, the company aimed to improve clinical outcomes for patients whose weight and hormonal health are deeply interconnected.

Key Market Players

• Pfizer Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Abbott Laboratories
• Merck & Co., Inc.
• Sanofi S.A.
• Eli Lilly and Company
• Bristol Myers Squibb Company
• Ferring Pharmaceuticals

By Surgery	By Drug	By Diagnosis	By End User	By Region
Ovarian Wedge Resection Cyst Aspiration Laparoscopic Ovarian Drilling	Ovulation Inducing Agents Insulin-Sensitizing Agents Oral Contraceptives Antiandrogens Anti-Depressants Insulin-Sensitizing Agents Anti-Obesity Drugs Others	Pelvic Examination Ultrasound Blood Tests	Hospitals & Clinics Ambulatory Surgical Centers Fertility Clinics	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global PCOS Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• PCOS Treatment Market, By Surgery:

• Ovarian Wedge Resection
• Cyst Aspiration
• Laparoscopic Ovarian Drilling

• PCOS Treatment Market, By Drug:

• Ovulation Inducing Agents
• Insulin-Sensitizing Agents
• Oral Contraceptives
• Antiandrogens
• Anti-Depressants
• Insulin-Sensitizing Agents
• Anti-Obesity Drugs
• Others

• PCOS Treatment Market, By Diagnosis:

• Pelvic Examination
• Ultrasound
• Blood Tests

• PCOS Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Fertility Clinics

• PCOS Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE